From:	< @)nhs.scot>
Sent: 27 April 2022	10:32	
To:		@novartis.com>
Subject: RE: Tende	ering Overview	-

Hi

I can possibly check timelines for new contract/extension start dates that we are hoping to deliver this year. Unfortunately I wouldn't know when exactly tenders will go out for each specific project.

Thank you

, National Procurement Procurement, Commissioning, Facilities

NHS National Services Scotland

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T: M: F: E: <u>@nhs.scot</u> https://www.nss.nhs.scot/

Please consider the environment before printing this email. NHS National Services Scotland is the common name for the Common Services Agency for the Scottish Health Service. <u>www.nhsnss.org</u>

From:	<	@novartis.com>
Sent: 27 April 2	022 09:11	
То:	<	@nhs.scot>
Subject: RE: Te	endering Overvi	ew

Hi

Thanks for that, it's much appreciated.

In the meantime, is there any document that has a timeline of when tenders are due to be released for planning purposes?

Regards,



From:	<	@nhs.scot>
Sent: 26 April 20	22 10:43	
To:	<	@novartis.com>
Subject: RE: Ter	ndering Ov	erview

This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Hi

Apologies we are all currently immersed in tendering, we will review dates and get back to you however in may be a couple of months when we can all schedule a suitable time, thanks again.

National Procurement Procurement, Commissioning, Facilities

NHS National Services Scotland

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T: M: F: E: <u>@nhs.scot</u> https://www.nss.nhs.scot/

Please consider the environment before printing this email. NHS National Services Scotland is the common name for the Common Services Agency for the Scottish Health Service. <u>www.nhsnss.org</u>

From: @novartis.com>
Sent: 26 April 2022 09:40
To: @novartis.com
Subject: RE: Tendering Overview

HI

Thanks for coming back to me, no problems, I thought that as you had awarded that you may be ok to discuss.

I completely understand your position and when we can have a catch up, that would be much appreciated.

Just for reference, I look after 53 established brands so it's a wide portfolio, hence my eagerness to learn more.

Regards,



This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Thank you for your email.

Due to ongoing Fingolimod Capsules award process unfortunately but I won't be able to schedule a call to go over the top line tendering process.

Thank you

, National Procurement Procurement, Commissioning, Facilities

NHS National Services Scotland

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T: M: F: E: <u>@nhs.scot</u> https://www.nss.nhs.scot/

Please consider the environment before printing this email. NHS National Services Scotland is the common name for the Common Services Agency for the Scottish Health Service. <u>www.nhsnss.org</u>

From:	@novartis.com>
Sent: 21 April 2022 09:38	
To: <	@nhs.scot>
Subject: Tendering Overview	

Hi

I hope all is well?

I'm still getting up to speed with the tendering landscape. Would you be able to have a call to go over the top line tendering process, what NHSS are trying to achieve and how we can best work together?

This isn't product specific, I'm aiming to do this in between any active tenders and above brand.

Kind Regards



United Kingdom GM / REGION EUROPE PHARMA Novartis Pharmaceuticals UK Limited 2nd Floor The West Works Building White City Place 195 Wood Lane London W12 7FQ



U NOVARTIS

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006 Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

This email is intended for the named recipient only. If you have received it by mistake,

please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006 Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

This email is intended for the named recipient only. If you have received it by mistake,

please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006 Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis

processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.